Genprex Inc reports results for the quarter ended December 31 - Earnings Summary

Genprex

01/04/2025 13:02

Genprex Inc GNPX.OQ reported a quarterly adjusted loss of $1.15​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-3.96.  The lone analyst forecast for the quarter was for a loss of 39 cents per share.

Reported revenue was zero​.

Genprex Inc's reported EPS for the quarter was a loss of $1.15​.

The company reported a quarterly loss of $4.61 million.

Genprex Inc shares had held steady so far this quarter and lost 71.2% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 35.5% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Genprex Inc is $7.50

This summary was machine generated from LSEG data April 1 at 12:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.39
-1.15
Missed
Sep. 30 2024
-1.93
-1.23
Beat
Jun. 30 2024
-2.30
-3.00
Missed
Mar. 31 2024
-2.54
-3.69
Missed